Alterity Therapeutics (ATHE) Operating Income (2009 - 2010)
Alterity Therapeutics' (ATHE) quarterly Operating Income came in at -$4.3 million in Q2 2010, up 24.02% year-on-year from -$3.5 million in Q2 2009, and up 24.02% quarter-over-quarter from -$5.7 million in Q2 2009.
Alterity Therapeutics (ATHE) Operating Income (2009 - 2010) Analysis & Trends
Alterity Therapeutics' Operating Income history runs 2 years deep, the most recent figure standing at -$4.3 million for Q2 2010.
- On a quarterly basis, Operating Income rose 24.02% year-over-year to -$4.3 million in Q2 2010; TTM through Jun 2010 was -$32.1 million, a 5.46% increase from a year earlier, with the FY2012 full-year figure at -$7.8 million, down 14.47% from the prior year.
- Operating Income grew to -$4.3 million in Q2 2010 per ATHE's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$4.3 million in Q2 2010 and bottomed at -$5.7 million in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alterity Therapeutics | 29.68 Bn | 29.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2010 | -4.34 Mn |
| Jun 30, 2009 | -5.71 Mn |